dsm-firmenich's Share Repurchase Program Overview
dsm-firmenich, a leader in nutrition, health, and beauty, has embarked on an ambitious share repurchase initiative aimed at returning value to shareholders and optimizing capital structure. This program is designed to cover commitments under its share-based compensation plans and reduce the issued capital significantly.
Initial Steps in the Repurchase Program
The journey began with the announcement made on February 13, 2025, where dsm-firmenich revealed plans to repurchase €1 billion in ordinary shares, starting with an initial fund of €500 million. This proactive approach reflects the company’s commitment to enhancing shareholder value amid a dynamic market environment.
Implementation of the Program
On April 1, 2025, the share repurchase program officially commenced. The company allocated €580 million for this purpose, which included €80 million earmarked specifically for its share-based compensation plans. This strategic allocation highlights the company’s focus on both rewarding employees and returning value to shareholders.
Recent Developments in the Program
With a keen awareness of market conditions, dsm-firmenich continued to adapt its strategy. On June 27, 2025, a notable increase was announced, elevating the total repurchase program to €1,080 million. This decision followed the successful completion of the sale of dsm-firmenich’s stake in the Feed Enzymes Alliance, enhancing liquidity and financial stability.
Current Share Repurchase Activity
As of the end of October 2025, dsm-firmenich reported a total of 441,421 shares repurchased in the period from October 27 to October 31, 2025. These shares were repurchased at an attractive average price of €73.00 each, culminating in a total investment of €32.2 million. Overall, since the program’s inception, dsm-firmenich has now repurchased 11,097,500 shares at an average price of €85.62, totaling an impressive €950.1 million.
Future Expectations for the Program
The company has set a completion date for this €1,080 million share repurchase program no later than January 30, 2026. This timeline reflects dsm-firmenich’s dedication to executing strategic capital management effectively while navigating changing market dynamics.
Investor Relations and Transparency
dsm-firmenich remains committed to transparency with its stakeholders. For more detailed information about the program, investor relations inquiries can be directed to their team at investors@dsm-firmenich.com.
About dsm-firmenich
dsm-firmenich is a cornerstone in the nutrition, health, and beauty sectors, dedicated to creating innovative solutions that promote well-being. With operations spanning nearly 60 countries and a workforce of approximately 30,000 employees, dsm-firmenich generates revenues exceeding €12 billion. The company's dual headquarters in Switzerland and the Netherlands symbolize its robust presence in global markets. By focusing on sustainability and utilizing cutting-edge technology, dsm-firmenich continues to support the growth and needs of a global population.
Frequently Asked Questions
What is the main goal of dsm-firmenich's share repurchase program?
The primary goal is to return value to shareholders and reduce the total issued capital of the company.
How much has dsm-firmenich allocated for the share repurchase program?
Initially, €1 billion was allocated, later increased to €1,080 million following strategic market evaluations.
What are the recent share repurchase figures?
As of late October 2025, dsm-firmenich has repurchased 441,421 shares for a total amount of €32.2 million.
When is the expected completion date for the share repurchase program?
The program is expected to conclude no later than January 30, 2026.
How does dsm-firmenich ensure transparency with investors?
dsm-firmenich emphasizes open communication through their investor relations team, providing updates and strategic insights regularly.
